Autolus Therapeutics Secures 10-Year Critical Raw Material Supply for CAR-T Products
Summary
Autolus Therapeutics secured a 10-year agreement with AGC Biologics for the supply of critical lentiviral vector, essential for its CAR-T product manufacturing, with a minimum commitment of EUR 25 million over five years.
Key Events
-
Secures Critical Supply Agreement
Autolus Limited, a subsidiary, entered into a Master Service Agreement with AGC Biologics S.p.A for the manufacture and supply of lentiviral vector, a critical raw material for CAR-T products.
-
Long-Term Operational Stability
The agreement has a fixed term of ten years, replacing a prior arrangement and ensuring long-term supply chain stability for clinical and commercial CAR-T production.
-
Significant Financial Commitment
The company committed to purchasing a minimum of 14 batches of lentiviral vector in the first two years and a minimum value of EUR 25 million in products and services during the subsequent five-year period.
Analysis
Autolus Therapeutics has entered into a significant 10-year Master Service Agreement with AGC Biologics for the supply of lentiviral vector, a critical raw material for its CAR-T product manufacturing. This agreement replaces a prior arrangement, ensuring long-term supply chain stability for both clinical and commercial use of its CAR-T therapies, including obe-cel. The commitment to purchase a minimum of EUR 25 million in products and services over the subsequent five-year period underscores the strategic importance of this partnership for the company's operational continuity and growth, especially following its recent positive revenue and guidance announcements.
At the time of this filing, AUTL was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $388.6M. The 52-week trading range was $1.11 to $2.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.